Literature DB >> 18467048

Emblica officinalis and hepatocarcinogenesis: a chemopreventive study in Wistar rats.

Sarwat Sultana1, Salahuddin Ahmed, Tamanna Jahangir.   

Abstract

INTRODUCTION: Emblica officinalis L. commonly known as gooseberry, Phyllanthus emblica, Emblica, Indian gooseberry, amla is used in Indian system of medicine for the treatment of liver ailments. AIM AND
OBJECTIVES: In the present study, we report that it ameliorates the carcinogenic response as it reverses the histopathological changes and reduces the number of gamma-GT-positive foci induced by Solt Farber protocol in the liver of Wistar rats.
MATERIALS AND METHODS: Tumors were induced by initiation with diethylnitrosoamine (DEN) (200 mg/kg body wt., i.p.) followed by promotion with 2-acetylaminoflourine (2-AAF) (0.02%, w/w in diet) for continuous 6 weeks and the animals were subjected to partial hepatectomy on day 21 of initiation.
RESULTS: Pretreatment with defatted methanolic fruit extract (100 and 200mg/kg b.w.) of Emblica officinalis showed significant partial recovery of pathological manifestations as compared to DEN and 2-AAF-treated group animals (p<0.001) and suppressed the tumor forming potential of 2-AAF (p<0.05) at both the doses.
CONCLUSION: Emblica officinalis has the potential to suppress carcinogen-induced response in rat liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467048     DOI: 10.1016/j.jep.2007.04.021

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  8 in total

1.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

2.  Bioactivities of alcohol based extracts of Phyllanthus emblica branches: antioxidation, antimelanogenesis and anti-inflammation.

Authors:  Bungorn Sripanidkulchai; Jintana Junlatat
Journal:  J Nat Med       Date:  2014-02-21       Impact factor: 2.343

3.  Herbal products: benefits, limits, and applications in chronic liver disease.

Authors:  Anna Del Prete; Antonella Scalera; Maddalena Diana Iadevaia; Agnese Miranda; Claudio Zulli; Laura Gaeta; Concetta Tuccillo; Alessandro Federico; Carmelina Loguercio
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-06       Impact factor: 2.629

Review 4.  Anticancer Properties of Phyllanthus emblica (Indian Gooseberry).

Authors:  Tiejun Zhao; Qiang Sun; Maud Marques; Michael Witcher
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

Review 5.  Natural Medicines Used in the Traditional Tibetan Medical System for the Treatment of Liver Diseases.

Authors:  Qi Li; Hai-Jiao Li; Tong Xu; Huan Du; Chen-Lei Huan Gang; Gang Fan; Yi Zhang
Journal:  Front Pharmacol       Date:  2018-01-30       Impact factor: 5.810

6.  Protective Assessment of Euphorbia neriifolia and its Isolated Flavonoid Against N-nitrosodiethylamine-induced Hepatic Carcinogenesis in Male Mice: A Histopathological Analysis.

Authors:  Veena Sharma; Pracheta Janmeda
Journal:  Toxicol Int       Date:  2014-01

7.  Anti-inflammatory Effects of Phyllanthus emblica L on Benzopyrene-Induced Precancerous Lung Lesion by Regulating the IL-1β/miR-101/Lin28B Signaling Pathway.

Authors:  Cheng-Cheng Wang; Jia-Rui Yuan; Chun-Fei Wang; Nan Yang; Juan Chen; Dan Liu; Jie Song; Liang Feng; Xiao-Bin Tan; Xiao-Bin Jia
Journal:  Integr Cancer Ther       Date:  2016-08-24       Impact factor: 3.279

8.  Antiproliferative activities and phenolic acid content of water and ethanolic extracts of the powdered formula of Houttuynia cordata Thunb. fermented broth and Phyllanthus emblica Linn. fruit.

Authors:  Piyawan Kumnerdkhonkaen; Somprasong Saenglee; Md Ali Asgar; Gulsiri Senawong; Kanoknan Khongsukwiwat; Thanaset Senawong
Journal:  BMC Complement Altern Med       Date:  2018-04-11       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.